Researchers have identified loss of Fiblin-2 as a marker of breast cancer progression since the protein is expressed by normal breast cells but lost in breast cancer cell lines and invasive breast tumors.
As further confirmation of Fibulin-2?s anti-invasion effect, reintroduction of the protein into Fibulin-2-negative breast cancer cells resulted in decreased cell migration and invasion in vitro.
Fibulin-2 is a known component of the extracellular matrix (the supportive protein structure surrounding cells) and is thought to be critical for cell migration during wound healing. However, loss of Fibulin-2 in breast cancer may lead to changes in the environment surrounding, and confining, cancer cells, thus enabling cancer cells to migrate from their original site to other locations.
Fibulin-2?s potential involvement in breast cancer spread may provide prognostic implications if loss of its expression can be directly correlated with the transition from noninvasive breast cancer to recurrent and/or invasive breast cancer. Future studies will explore the exact mechanisms by which Fibulin-2 mediates its anti-invasion effect.
This work was lead by Dr. Michael A. Hollingsworth at the University of Nebraska Medical Center, Omaha, Nebraska, and supported by the Department of Defense and the National Institutes of Health.
Yi CH, Smith DJ, West WW, Hollingsworth MA. Loss of Fibulin-2 expression is associated with breast cancer progression. Am J Pathol 2007 170: 1535?1545.